US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce.

Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...

Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s ...

Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...

After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...

Sage Therapeutics Inc.'s stock slid 4.7% Thursday, after the biotech said it's cutting about 33% of its workforce as part of an overhaul of its business and pipeline that's expected to extend its cash ...

Sage and Biogen last year won Food and Drug Administration approval of Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major depressive disorder, a much ...

Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 ...

Sage Therapeutics announces a reorganization to support product launch and pipeline development, resulting in a workforce ...

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...

The layoffs will extend the company’s cash runway and allow it to continue investing in the recent launch of the postpartum ...